The acquisition, significantly, enriches GammaDelta Therapeutics' innovative platform based on tissue-delta gamma T cells. The two complementary technologies have the potential to develop new immunotherapies designed to treat a wide range of oncological diseases, both hematological and solid tumors.

 

“This transaction represents a milestone for Biotechnology sector in Portugal and I am confident that GammaDelta Therapeutics is the right partner to help bring our DOT-Cells technology to patients. We are taking a decisive step in this direction and confirming the scientific value of biomedical research carried out in Portugal. At the same time, we are also giving a clear signal that Portuguese entrepreneurship is aware of the potential of life sciences sector and is managing to develop it ”, says Diogo Remechido Anjos, co-founder, ex-president and CEO of Lymphact, adding that "this would not be possible without a fantastic team".

 

“Gamma Delta Therapeutics has its own technology that is highly complementary to our DOT cells; therefore, the potential for synergies is immense. On the other hand, we are very excited to have access to the exceptional means of GDT to make it possible to bring DOT-Cells to the clinic ”, said Bruno Silva-Santos, the main scientist behind Lymphact.

 

Paolo Paoletti, CEO of GammaDelta Therapeutics, said: "We are excited about the potential of Lymphact's technology and believe that it complements our technology, which will help us advance our mission of offering new treatments for cancer patients using Gamma Delta T cells. Vδ1. "

 

The President of Portugal Ventures, Rita Marques, says that “with this operation, we are projecting Portugal to the world, exporting national knowledge and technology, with a relevant socio-economic impact. We believe that this success case will leverage other cases in the future, with the potential to multiply projects in Life and Health Sciences originating in Portugal, which will continue to arouse the interest of international economic agents in technological innovation. ”

 

To the President of Busy Angels , Luís Mira Amaral, "this acquisition feeds our initial dream of being able to support an impactful technology, studied and developed in Portugal, with the capacity to reach cancer patients worldwide".